Follow
Vicki Osborne
Vicki Osborne
Drug Safety Research Unit
Verified email at dsru.org
Title
Cited by
Cited by
Year
Remdesivir in treatment of COVID-19: A systematic benefit–risk assessment
M Davies, V Osborne, S Lane, D Roy, S Dhanda, A Evans, S Shakir
Drug safety 43, 645-656, 2020
862020
Lopinavir-ritonavir in the treatment of COVID-19: a dynamic systematic benefit-risk assessment
V Osborne, M Davies, S Lane, A Evans, J Denyer, S Dhanda, D Roy, ...
Drug safety 43 (8), 809-821, 2020
742020
Non-medical opioid use in youth: Gender differences in risk factors and prevalence
V Osborne, M Serdarevic, H Crooke, C Striley, LB Cottler
Addictive behaviors 72, 114-119, 2017
682017
Incidence of venous thromboembolism in users of strontium ranelate
V Osborne, D Layton, M Perrio, L Wilton, SAW Shakir
Drug safety 33 (7), 579-591, 2010
442010
Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK?
S Dhanda, V Osborne, E Lynn, S Shakir
BMJ evidence-based medicine, 2020
372020
The association between insomnia and prescription opioid use: results from a community sample in Northeast Florida
M Serdarevic, V Osborne, CW Striley, LB Cottler
Sleep health 3 (5), 368-372, 2017
332017
Reported adverse events with painkillers: data mining of the US Food And Drug Administration adverse events reporting system
J Min, V Osborne, A Kowalski, M Prosperi
Drug safety 41 (3), 313-320, 2018
322018
Sex differences in patterns of prescription opioid non-medical use among 10–18 year olds in the US
V Osborne, CW Striley, SJ Nixon, AG Winterstein, LB Cottler
Addictive behaviors 89, 163-171, 2019
292019
Power of the peer and parent: gender differences, norms, and nonmedical prescription opioid use among adolescents in South Central Kentucky
KL Egan, E Gregory, VL Osborne, LB Cottler
Prevention science 20 (5), 665-673, 2019
232019
Safety of intranasal quadrivalent live attenuated influenza vaccine (QLAIV) in children and adolescents: a pilot prospective cohort study in England
R McNaughton, E Lynn, V Osborne, A Coughtrie, D Layton, S Shakir
Drug safety 39 (4), 323-333, 2016
212016
A longitudinal analysis of the substance abuse, violence, and HIV/AIDS (SAVA) syndemic among women in the criminal justice system
AA Jones, T Gerke, CW Striley, V Osborne, N Whitehead, LB Cottler
Journal of psychoactive drugs 51 (1), 58-67, 2019
192019
Indicators of drug-seeking aberrant behaviours: the feasibility of use in observational post-marketing cohort studies for risk management
D Layton, V Osborne, M Al-Shukri, SAW Shakir
Drug safety 37 (8), 639-650, 2014
132014
Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management
V Osborne, M Davies, D Roy, F Tescione, SAW Shakir
BMJ evidence-based medicine 25 (6), 199-205, 2020
122020
Utilisation of extended release quetiapine (Seroquel XL™): Results from an observational cohort study in England
V Osborne, M Davies, D Layton, SAW Shakir
European Psychiatry 33 (1), 61-67, 2016
112016
Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care …
A Evans, M Davies, V Osborne, D Roy, S Shakir
BMJ open 10 (11), e038102, 2020
102020
Utilization of fentanyl buccal tablets in England: Exploring off‐label use reported in a cohort study
V Osborne, D Layton, C Fogg, M Al‐Shukri, SAW Shakir
European Journal of Pain 18 (4), 506-512, 2014
102014
Utilisation and safety of deferasirox: results from an observational cohort study in England
V Osborne, M Davies, D Layton, SAW Shakir
Drug safety 41 (3), 267-275, 2018
92018
What Is the Difference Between Observed Association and Causal Association, Signals and Evidence? Examples Related to COVID-19
V Osborne, SAW Shakir
Frontiers in Pharmacology 11, 2020
72020
Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring data
D Layton, VM Osborne, A Gilchrist, SAW Shakir
Drug safety 34 (12), 1177-1189, 2011
72011
Implications of off-label use: An example from the final results of an observational cohort study on Intrinsa®(testosterone patch)
V Osborne, D Layton, SAW Shakir
Post reproductive health 20 (2), 48-54, 2014
62014
The system can't perform the operation now. Try again later.
Articles 1–20